A PLA1-2 punch regulates the Golgi complex by Bechler, Marie E et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A PLA1-2 punch regulates the Golgi complex
Citation for published version:
Bechler, ME, de Figueiredo, P & Brown, WJ 2012, 'A PLA1-2 punch regulates the Golgi complex' Trends In
Cell Biology, vol. 22, no. 2, pp. 116-24. DOI: 10.1016/j.tcb.2011.10.003
Digital Object Identifier (DOI):
10.1016/j.tcb.2011.10.003
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Trends In Cell Biology
Publisher Rights Statement:
Available under Open Access
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
A PLA1-2 Punch Regulates the Golgi Complex
Marie E. Bechler, Paul de Figueiredo1, and William J. Brown*
Department of Molecular Biology & Genetics, Cornell University, Ithaca, NY 14853
1Borlaug Research Center, Department of Veterinary Pathobiology, Department of Microbial &
Molecular Pathogenesis & Department of Plant Pathology and Microbiology, Texas A&M
University, College Station, TX 77843
Abstract
The mammalian Golgi complex, trans Golgi network (TGN) and ER-Golgi-Intermediate
Compartment (ERGIC) are comprised of membrane cisternae, coated vesicles and membrane
tubules, all of which contribute to membrane trafficking and maintenance of their unique
architectures. Recently, a new cast of players was discovered to regulate the Golgi and ERGIC:
four unrelated cytoplasmic phospholipase A (PLA) enzymes, cPLA2α (GIVA cPLA2), PAFAH Ib
(GVIII PLA2), iPLA2-β (GVIA-2 iPLA2), and iPLA1γ. These ubiquitously expressed enzymes
regulate membrane trafficking from specific Golgi subcompartments, although there is evidence
for some functional redundancy between PAFAH Ib and cPLA2α. Three of these enzymes,
PAFAH Ib, cPLA2α, and iPLA2-β, exert effects on Golgi structure and function by inducing the
formation of membrane tubules. Here, we review our current understanding of how PLA enzymes
regulate Golgi and ERGIC morphology and function.
Cytoplasmic PLA enzymes associated with the Golgi complex
The functional organization of the mammalian Golgi complex is controlled by myriad
proteins and enzymes that regulate the production of coated vesicles and membrane tubules
for cargo export and the overall architecture of the Golgi ribbon [1]. At the heart of these
processes is the Golgi complex itself, where form and function dance to the tune of secretory
demand. Golgi membranes are dynamically modified to form membrane vesicles and
tubules, which carry secretory cargo and maintain the morphological and functional integrity
of the organelle (Box 1). For example, a sudden increase in secretory load results in the
formation of intercisternal membrane tubules that facilitate anterograde trafficking through
the Golgi stack [2]. Conversely, altering the ability of Golgi membranes to form vesicles and
tubules dramatically changes Golgi architecture and secretory function [1, 2].
The first indication that cytoplasmic PLA activity was important for Golgi function came
from a screen that showed PLA antagonists can inhibit brefeldin A (BFA)-induced
membrane tubule formation from the Golgi complex and TGN [3, 4]. Subsequent studies
suggested that the dynamic and continual formation of these PLA-dependent membrane
tubules is important for several normal functions including assembly and maintenance of an
intact Golgi ribbon [5], retrograde trafficking from the cis Golgi and ERGIC to the
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endoplasmic reticulum (ER) [6], and export from the TGN (Box 1) [7]. Until the
identification of four Golgi-associated cytoplasmic PLA enzymes, no specific PLA enzymes
had been directly linked to membrane tubule formation or Golgi function. Three of these
PLA enzymes (cPLA2α, iPLA2-β and Platelet Activating Factor Acetylhydrolase Ib
[PAFAH Ib]) hydrolyze at the sn-2 position of phospholipids [8, 9]. cPLA2α and iPLA2-β
also possess lysophospholipase and transacylase activities in vitro and in vivo. A fourth
enzyme, iPLA1γ hydrolyzes fatty acid substrates from the sn-1 position of phospholipids
[10]. Each of these PLA enzymes influence Golgi function, and in at least three cases, have
direct effects on the ability of the Golgi to form membrane tubules. Additional PLA
enzymes are reported to associate with Golgi membranes, including GIV PLA2δ (cPLA2δ)
[11] and Group V secretory PLA2 [12]. However, possible roles for these proteins in
regulating Golgi structure and function are unknown. Therefore, we will restrict our
discussion to the aforementioned four recently identified PLA enzymes.
PLA2 enzymes are members of a superfamily of PLAs that cleave fatty acids at the sn-2
position of glycerol phospholipids to generate a free fatty acid and a lysophospholipid [13,
14]. These enzymes are grouped (I-XV) according to sequence similarities and functions [8].
Importantly, the two products of phospholipid hydrolysis, lysophospholipids and free fatty
acids, function in signal transduction, phospholipid synthesis, and membrane remodeling
[15]. Thus, PLA2 enzymes are associated with functions that at first glance would not appear
to have any involvement with the Golgi complex. Recently, however, studies have suggested
that many phenotypes associated with loss of PLA2 function may be due to alterations in
Golgi membrane trafficking capacity (Table I provides basic information on the four
enzymes discussed in this review).
Mechanistically, cytoplasmic PLA enzymes could influence the structure and function of the
Golgi complex in several ways [3]. First, they could directly regulate membrane tubule and
vesicle formation through the production of positive curvature-inducing lysophospholipids
[16]. Second, PLA enzymes could generate lipid products that recruit effector proteins to
Golgi membrane domains [17]. Third, they could generate lysophospholipids and fatty acids
that influence downstream signal transduction and metabolic pathways. Finally, changes in
membrane structure could occur via mechanisms that are independent of lipase activity, as
will be discussed below. The discovery of four different cytoplasmic PLAs that regulate the
Golgi complex is a surprising development, establishing new functions for these enzymes
and revealing an unexpected level of complexity to Golgi structure and membrane
trafficking. Here, we provide a brief summary of these enzymes, their enzymatic activities,
links to previously described functions, and a more extensive discussion of recent functional
studies that have uncovered new roles in regulating the functional organization of the
ERGIC/Golgi complex.
cPLA2α
cPLA2α is a ubiquitously expressed cytoplasmic Group IV PLA2 (gene name PLA2G4A). It
is the best studied cytoplasmic PLA2 and has been extensively reviewed elsewhere [15, 18]
(Table 1). cPLA2α contains a C2 Ca2+-binding domain that is required for translocation to
membranes. Upon membrane binding, phospholipid hydrolysis occurs by the PLA2α active
site serine-aspartic acid dyad (Figure 1). cPLA2α is best known for its central role in
mediating eicosanoid biogenesis in animal cells, catalyzing the release of arachidonic acid
from membrane phospholipids [15, 18]. Arachidonic acid and its metabolites – including
prostaglandins and leukotrienes that are produced by cyclooxygenases and lipoxygenases,
respectively – are bioactive lipids that mediate diverse processes, including inflammation,
smooth muscle contraction and cell growth [14].
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Although early work suggested a role for PLA2 activity in regulating diverse intracellular
membrane trafficking events [3], the observation that cPLA2α regulates the structure and
function of the Golgi complex was unanticipated. The first clues suggesting this possibility
came when cPLA2α was shown to influence secretory cargo trafficking and be recruited to
the Golgi complex in response to transient increases in cytoplasmic Ca2+ and other stimuli
[19-22]. Recent work [23, 24] provided confirmation and further insight into this newly
attributed role for cPLA2α in Golgi function.
These recent studies extended previous work, which found that cPLA2α was recruited to the
Golgi complex in endothelial cells upon reaching confluency [21, 22], by showing that
cPLA2α contributes to the delivery of transmembrane proteins to junction complexes in
confluent endothelial cells [24]. RNAi and specific enzyme antagonists were used to show
that loss of cPLA2α prevented delivery of VE-cadherin, occludin, and claudin-5 to cell-cell
contacts, resulting in accumulation of these transmembrane proteins in the Golgi complex.
These studies, however, did not identify the nature or location of the trafficking block.
Another study found that arrival of a secretory bolus at the Golgi complex induced the Ca2+-
dependent translocation of cPLA2α from the cytoplasm to Golgi membranes [23]. Live-cell
imaging and electron microscopy experiments revealed that cPLA2α mediates the formation
of intercisternal tubular connections in the Golgi. Moreover, multiple approaches not only
demonstrated that Golgi membrane tubulation was suppressed by loss or inactivation of
cPLA2α activity, but also that anterograde intra-Golgi trafficking of several cargo proteins
was blocked under these conditions. These data indicate that intercisternal tubules, formed
through the activity of cPLA2α enzymes, are crucial to these trafficking events (Figure 2).
Finally, the authors found that antagonists of cyclooxygenase and lipoxygenase activities
had no influence on Golgi membrane tubule formation and that the addition of arachidonic
acid to cells depleted of cPLA2α did not reverse the Golgi tubulation defect. Taken together,
these data strongly support the conclusion that cPLA2α activity drives Golgi membrane
tubulation and that this process occurs independent of the downstream biosynthesis of
bioactive metabolites [18]. In addition, these studies also provide support for diffusion-based
cis-to-trans intra-Golgi trafficking via tubular continuities [2, 25], at least under some
circumstances (see [1] for a review of transport across the Golgi stack).
Several tantalizing questions about cPLA2α regulation of Golgi structure and function
remain. cPLA2α displays a strong preference for phospholipids with sn-2 arachidonyl acyl
chains suggesting that homeostasis of arachidonyl-containing phospholipids may be crucial
in regulating Golgi structure and function. The molecular mechanisms that target cPLA2α
specifically to Golgi membranes, as well as membranes of the ER and the nucleus, are not
well established [18]. It has been proposed that the relative amount of phosphatidylcholine
(PC), cholesterol, and/or ceramide-1-phosphate in Golgi membranes may dictate the affinity
of cPLA2α for this organelle [26-28]. In addition, the C2 domain of cPLA2α mediates its
Ca2+-dependent translocation to the Golgi complex [18]. When this domain binds Ca2+, the
electrostatic potential of the surface-exposed Ca2+ binding loop is reduced and the
association of the neutralized C2 domain with organelle membranes in general, and PC in
particular, is promoted [29-31]. It is notable that the C2 domain of cPLA2α displays a
tendency to bind the cis and medial regions of the Golgi complex, whereas the related C2
domains of protein kinase Cα and synaptotagmin display selectivity for the TGN and the
plasma membrane [19]. This unique property of the cPLA2α C2 domain therefore may
account for the role of cPLA2α in intra-Golgi transport, and the apparent lack of enzyme
function in mediating trafficking associated with the TGN or plasma membrane. Finally,
cPLA2α binding to Golgi membranes requires less cytosolic Ca2+ than binding to the ER
[19]. This observation is consistent with the possibility that large increases in intracellular
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Ca2+ concentration alter the biological function of cPLA2α from regulating intra-Golgi
transport to mediating the massive generation of arachidonic acid from ER membranes.
The recruitment of cPLA2α to Golgi membranes likely results from the transient and local
release of Ca2+ from this organelle that occurs in response to increased secretory trafficking
load [23, 32]. A KDEL receptor-mediated signaling cascade that initiates from the Golgi
complex upon arrival of traffic from the ER may also regulate this process [33]. cPLA2α
translocation to membranes is necessary but not sufficient for catalytic activity, and enzyme
phosphorylation is also required for maximal catalytic activity in vitro and in vivo [34]. The
mechanisms by which Ca2+ transients and protein phosphorylation coordinately regulate
cPLA2α activity on Golgi membranes in vivo remain to be determined.
Finally, the cPLA2α knockout mouse does not exhibit profound defects in growth or
viability [35, 36]. Moreover, a human patient with inherited cPLA2α deficiency carrying
loss-of-function mutations in both cPLA2α alleles has globally decreased eicosanoid
production and suffers from intestinal ulcers as well as platelet dysfunction [37-39]. These
data demonstrate that cPLA2α activity itself is not essential for organismal viability, and
suggest that other PLA2 activities compensate for the loss of activity or ablation of this
enzyme in humans and whole animal model systems, respectively [18]. In support of this, an
siRNA screen in which the expression of PLA2s of the Group IV, VI, VII and VIII PLA2
families were knocked down in cPLA2α-deficient fibroblasts found that the Group VIIIA
enzyme, PAFAHIB, also contributes to anterograde transport of secreted cargo through the
Golgi complex [23]. These data establish that redundant PLA2 pathways can mediate intra-
Golgi trafficking.
PAFAH Ib
The discovery that PAFAH Ib (Platelet Activating Factor Acetylhydrolase Ib) is involved in
Golgi trafficking was equally unexpected. PAFAH Ib is a protein complex comprised of two
PLA2 subunits, α1 (gene name PAFAHIB2) and α2 (gene name PAFAHIB3), and a dimer of
a third non-catalytic subunit, the dynein regulator Lis1 (gene name PAFAH1B1) (Figure 1;
Table 1). The α1 and α2 subunits, which are 63% identical at the amino acid level, can form
catalytically active, Ca2+-independent homo- and heterodimers, with modest differences in
rates of hydrolysis and substrate preference [40-42]. The active site contains a catalytic triad
of serine, aspartic acid and histidine [43, 44]. PAFAH Ib was originally purified based on its
ability to hydrolyze the extracellular, inflammatory signaling lipid, PAF, which has an acetyl
group in its sn-2 position [45, 46]. Subsequent studies, however, indicated that cytoplasmic
PAFAH Ib is not involved in global downregulation of PAF signaling [47, 48]. Instead, both
α1 and α2 are partially localized on Golgi membranes and purified catalytically active, but
not inactive, subunits induce Golgi membrane tubule formation in a cell-free reconstitution
system [49]. Knockdown and overexpression experiments revealed that both PLA2 activity
and Lis1 binding are important for the assembly and maintenance of the Golgi complex.
RNAi knockdown and rescue experiments demonstrated that re-expression of wild type but
not catalytically inactive α1 restored export from the TGN to the cell surface, revealing that
the PLA2 activity of PAFAH Ib contributes to secretory efficiency. Reduction in both α1
and α2 levels resulted in Golgi, ERGIC and TGN fragmentation into numerous ‘mini-
stacks’, indicating that PAFAH Ib plays a role in the dynamic formation of membrane
tubules that link Golgi stacks into an intact ribbon (Figure 2). Imaging of live cells treated
with PLA2 and dynein antagonists confirmed the importance of these proteins in membrane
tubule-dependent Golgi assembly into an intact ribbon [50].
These results suggest that PAFAH Ib can link PLA2-mediated membrane tubule formation
with subsequent movement along microtubules (Figure 3). Recent studies have shown that
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Lis1, the causative agent of human lissencephaly [51], recruits dynein to the plus ends of
microtubules [52]. Once at the plus end, dynein activity is stimulated by Ndel1, a known
Lis1 and dynein binding partner [53]. This activation would allow the Lis1-dynein-Ndel1
complex to transport cargo to the minus ends of microtubules [54]. We propose that the
catalytic dimers, α1 and α2, when bound to Lis1, initiate PLA2-dependent membrane
curvature, thus forming membrane tubules. Subsequently, Lis1 binds to a Lis1-Ndel1-dynein
complex, facilitating the minus end movement of membrane tubules along microtubules
towards the microtubule organizing center. This mechanism couples the formation of Golgi
membrane tubules to dynein motors for the assembly and maintenance of a centrally located,
intact Golgi ribbon. Currently, it is not known if any lissencephaly phenotypes result from
functional changes at the Golgi complex.
In addition to the ERGIC, Golgi and TGN, various endosomal compartments also exhibit
membrane tubular extensions, which were originally shown to be involved in receptor
segregation, sorting and trafficking [55, 56] and inhibited by PLA2 antagonists [57, 58].
Recently, PAFAH Ib α1 and α2 subunits were also found to localize to early sorting
endosomes and the endocytic recycling compartment [59] (Figure 2). RNAi knockdown and
overexpression experiments demonstrated that α1 and α2 are required for endosome
membrane tubule formation and the recycling of transferrin and transferrin receptors from
endosomes, functions that are dependent on PLA2 activity but independent of Lis1. These
results show that PAFAH Ib α1 and α2 can function at different compartments by
controlling the formation of membrane tubules that contribute to intracellular trafficking.
These results raise several issues. First, PAFAH Ib has a strict in vitro substrate preference
for PAF and its analogs, which have an acetyl group in the sn-2 position and are generally
associated with extracellular signaling during inflammation [60]. It is unclear if PAF also
serves a function in Golgi and endosome membranes or if PAFAH Ib hydrolyzes other
substrates in vivo. Second, α1-/-/α2-/- mice are reasonably normal except for severe male
spermatogenesis defects [47, 48], indicating that other cytoplasmic PLA2 enzymes
compensate for their loss. Third, although α1 and α2 can form functional homo- and
heterodimers, a variety of studies show that they are not completely redundant. For example,
α1-/- mice exhibit no detectable phenotypes, whereas α2-/- mice have mild spermatogenesis
defects [47, 48]. In addition, α1 and α2 have different phospholipid head group preferences,
catalytic rates when bound to Lis1, developmental expression patterns [61], and neurological
phenotypes in mutant backgrounds [62]. Consistent with these studies, the knockdown of
individual α1 or α2 results in noticeably different effects on Golgi morphology and secretory
trafficking (M. Bechler and W. Brown, unpublished data). Therefore, it may be more
appropriate to conclude that α1 homodimers and α2 homodimers have both overlapping and
distinct functions.
iPLA2-β
iPLA2–β belongs to the Group VI family of cytoplasmic, Ca2+-independent PLA2 enzymes
(also called iPLA2B, GVIA-2 iPLA2 and PNPLA9) (Table 1) [15]. Human iPLA2–β is a
ubiquitously expressed 85 kD protein with 7 ankryin repeats and an active site serine within
a consensus lipase motif (GXSXG) in the C-terminal patatin domain (Figure 1). iPLA2–β
can yield several splice variants. The full-length protein (also called L-iPLA2) is
catalytically active but with relatively little fatty acid substrate preference [63], whereas the
two smaller alternatively spliced variants, ankryin-iPLA2-1 and ankryin-iPLA2-2, are
missing the lipase active site. Interestingly, these catalytically inactive variants appear to
modulate the activity of L-iPLA2 and the ratio of L-iPLA2 to ankryin-iPLA2 determines
overall iPLA2-β activity, likely as a result of forming oligomers [64]. iPLA2-β is associated
with a variety of functions and pathologies including adipocyte differentiation [65], glucose-
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mediated insulin secretion [66] and neurodegenerative disease [67, 68], and has been
reviewed elsewhere [8, 69]. Recent studies, however, show that iPLA2-β plays a role in
regulating the ERGIC through the formation of membrane tubules [70].
The ERGIC is very closely associated with the cis Golgi but is considered an independent
compartment from the Golgi proper [71, 72]. It is comprised of a complex array of
tubulovesicular membranes that serve as an intermediate compartment in bidirectional
trafficking between the ER and Golgi complex. The ERGIC is an active site of COPI vesicle
formation for retrograde trafficking back to the ER [71]. Recruitment of COPI vesicle
proteins to ERGIC and Golgi membrane requires activation of the Arf family of GTP
binding proteins by their cognate guanine nucleotide exchanges factors (GEFs) [73]. Double
knockdown of Arf1 and Arf4 causes dispersal of COPI proteins and stimulation of ERGIC
membrane tubules [74] COPI vesicle budding is inhibited by brefeldin A (BFA), which
forms abortive BFA:Arf-GEF complexes thereby preventing Arf activation [75]. As a
consequence of BFA treatment, and siRNA-mediated knockdown of Arf GEFs, the ERGIC
and Golgi generate membrane tubules instead of vesicles [76, 77].
These recent studies provide evidence that ERGIC membrane tubules are dependent on
iPLA2-β in conditions of Arf1 and Arf4 knockdown. First, using live cell imaging, the
authors found that ERGIC membrane tubules continuously grow and shrink in Arf1 and
Arf4 knockdown cells, but that the overall morphology of the ERGIC was largely
unaffected. Second, the formation of ERGIC membrane tubules was inhibited by antagonists
of Ca2+-independent PLA2 enzymes, but not those of Ca2+-dependent enzymes. These
observations therefore ruled out cPLA2α. More definitive evidence came from siRNA
knockdown experiments, which showed that decreased levels of L-iPLA2 inhibited ERGIC
membrane tubules formed in Arf1/4-deficient cells. Moreover, iPLA2-β translocates from
the cytoplasm to the ERGIC membranes upon Arf1/4 knockdown. Importantly, the effects
of iPLA2-β knockdown on ERGIC tubules were not limited to the special circumstance of
Arf1/4-deficient cells, as the ERGIC membrane tubules that formed following temperature
shift experiments were similarly reduced. Although the exact function of these membrane
tubules is not fully established, secretory cargo can move between ERGIC clusters via
membrane tubules.
These results strongly implicate iPLA2-β in the formation of ERGIC membrane tubules
(Figure 2). It is suggested that Arf1/4 may negatively regulate the activity of iPLA2-β, which
was shown by pull-down assays to interact with Arf1. Thus, loss of Arf1/4 would activate
iPLA2-β and enhance the formation of ERGIC membrane tubules. Consistent with a role in
membrane trafficking, iPLA2-B is recruited to the juxtanuclear Golgi region in response to
secretory stimuli in pancreatic β–cells [78], and insulin secretion is reduced in PLA2G6
(gene symbol for iPLA2-β) null mice [79].
Interestingly, mutations in the human PLA2G6 gene result in several childhood neurological
disorders including infantile neuroaxonal dystrophy (INAD) and idiopathic
neurodegeneration with brain iron accumulation (NBIA) [80], which have been recapitulated
in mouse models [81, 82]. These autosomal recessive neurodegenerative disorders, now
referred to as PLA2G6-associated neurodegeneration (PLAN), cause severe cognitive and
motor regression [83]. PLA2G6 knockout mice also display other defects including impaired
hypercontractility in endothelial cells [84]. Currently, the connection between iPLA2-β
function at the ERGIC and disease manifestations in PLAN is not understood, but it is
tempting to speculate that neuronal abnormalities could arise from defects in secretory
trafficking.
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iPLA1γ
iPLA1γ (gene name DDH2) is a phosphatidic acid (PA)-specific PLA1 enzyme [85, 86] and
member of the iPLA1 family of proteins that also includes PA-iPLA1 (iPLA1α) and p125
(iPLA1β) [87] (Table 1). iPLA1 enzymes hydrolyze the sn-1 bond of phospholipids to
produce lysophospholipids and fatty acids and are involved in a variety of functions
including membrane trafficking (Figure 1). For example, mammalian iPLA1β is implicated
in regulating ER-Golgi function and interacts with the COPII vesicle component, Sec23p
[88, 89].
Although iPLA1γ localizes to the Golgi complex , its role in regulating membrane
trafficking is less clear than the other PLAs. Overexpression of iPLA1γ causes the ERGIC
and Golgi to become dispersed. Based on results from siRNA knockdown, iPLA1γ was
suggested to be involved in BFA-induced retrograde trafficking from the Golgi complex to
the ER, and in maintaining the morphological integrity of the Golgi [85]. Subsequent
studies, however, found that the siRNA used in these studies also caused an off-target loss of
Rab6 [86], a key GTPase involved in retrograde trafficking [90], which could be responsible
for the retrograde trafficking and Golgi loss phenotype. Using other siRNAs that did not
result in reduction of Rab6, loss of iPLA1γ did not inhibit BFA-induced membrane tubules
or disrupt Golgi structure [86]. Instead, loss of iPLA1γ had a modest kinetic effect on
trafficking of the temperature-sensitive vesicular stomatitus virus G protein (VSV-G) from
the Golgi to the plasma membrane but not from the ER to the Golgi. Interestingly, iPLA1γ
appears to be more closely associated with the cis Golgi, and it rapidly cycles on and off
Golgi membranes as shown by fluorescent recovery after photobleaching experiments.
Unlike catalytically inactive PAFAH Ib [49], mutating the catalytic serine (S351A) of
iPLA1γ reduced its ability to localize to Golgi membranes [85].
Exactly how iPLA1γ contributes to Golgi trafficking is unclear. If it is primarily localized to
the cis Golgi, then we might expect that it functions early in the Golgi and is not directly
involved in export from the TGN. One possibility is that iPLA1γ contributes to anterograde
transport through the Golgi stack, exerting its effect at an early stage (Figure 2). It is also
uncertain whether the phospholipase activity of iPLA1γ is required for its Golgi function,
which will be important for understanding its potential role in trafficking.
Concluding remarks
Cytoplasmic PLA enzymes historically have been associated with signal transduction
pathways; however, the reports reviewed here show that these enzymes have important
functions in directly regulating membrane structure and function. Indeed, membrane tubule
formation via the activity of cytoplasmic PLA enzymes has been understudied for many
years, and we have just begun to reveal a new layer of complexity in regulation of
trafficking through the Golgi complex. Although many unresolved questions remain or have
arisen (Box 2), recent studies have shed light on a long-standing puzzle: what is the
molecular relationship between membrane tubules and COPI coated vesicles? Using in vitro
reconstitution assays, a recent study revealed an intimate relationship between COPI coated
vesicles and membrane tubules, which is mediated by the opposing activities of cPLA2α and
an integral membrane lysophospholipid acyltransferase, LPAAT3(γ) [91]. Their studies
suggest that COPI proteins first drive bud formation from Golgi membranes, and then
tubules or vesicles can arise depending on the relative strength of cPLA2α and LPAAT3(γ)
activities. Following COPI bud formation, cPLA2γ promotes the formation of COP1
membrane tubules, whereas LPAAT3(γ) promotes the fission of vesicles. These results are
consistent with previous studies which found that LPAAT3(γ), a lysophosphatidic acid
specific acyltransferase, negatively regulates membrane tubule formation [92]. Thus, under
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normal conditions, the formation of COPI vesicles would be dictated by a balance of
cPLA2α and LPAAT3(γ) activities. PLA2-driven membrane tubules, however, are not
dependent on COPI proteins to initiate membrane bending, as clearly demonstrated by in
vitro reconstruction experiments [49] and BFA treatment in vivo [76, 93-95].
Another important question to address is how are PLA enzymes targeted to the Golgi
complex? With the exception of cPLA2α, where insights into enzyme targeting have begun
to emerge, the mechanisms by which other PLAs selectively target organelle membranes
remain unclear. One possible mechanism was recently suggested by the observation that
PAFAH Ib α1 selectively binds to phosphatidylinositol 3- and 4-phosphate (PI3P and PI4P)
[59], which are specific markers for endosomes and the Golgi complex, respectively [96,
97]. In addition, bioinformatic analyses of molecular interaction or co-expression database
resources for molecules that interact with PLA enzymes may also provide starting points for
interrogating this question.
The exact mechanism(s) by which PLA enzymes produce membrane curvature to generate
tubules is not clear and will require reconstitution systems to definitively address this issue.
The two hydrolysis products, lysophospholipids and fatty acid, may directly initiate
membrane shape change by altering curve-inducing properties in one leaflet of the
membrane [98]. Inhibiting the metabolism of arachidonic acid to downstream products does
not prevent PLA2-dependent membrane tubulation, at least in some circumstances, thus
arguing that accumulation of positive curve-inducing lysophospholipids is important [3, 4,
23]. Lysophospholipids and fatty acids may also aid in recruiting effector proteins to drive
tubule and vesicle formation [98]. In addition, they may indirectly serve as secondary
messengers to induce longer term effects or be funneled into other metabolic pathways.
Finally, hydrolysis-independent mechanisms could also influence tubule formation. The
enzymes themselves could contribute to membrane bending by virtue of their interaction
with the cytoplasmic leaflet. For example, the C2 domain of cPLA2α inserts into membranes
when bound to Ca2+ [18], and C2 domains of other proteins such as synaptotagmin and
Doc2 also insert into membranes and induce tubule formation [99-101]. Thus, the C2
domain of cPLA2α could play a similar role. In addition, Golgi membrane tubule formation
in vivo is often facilitated by microtubules and their associated motor proteins [102]. PLA2
enzymes and microtubule motors may intereact to coordinate membrane tubule formation,
as evidenced by the connection between PAFAH Ib, Lis1 and dynein [49]. However, the
details of these interactions and whether other PLA2 enzymes have cytoskeletal associations
remain unclear. Future studies will no doubt focus on the molecular mechanisms by which
PLA enzymes are integrated into the extensive machinery that controls the functional
organization of the Golgi complex.
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Box 1 Membrane Trafficking in the Secretory and Endocytic Pathways
Trafficking through the secretory pathway involves coated vesicles and membrane
tubules that sort, package, and transport material between organelles. These pathways
usually define cycles of vectoral movement of cargoes for secretion, which are coupled to
recycling pathways for bulk membrane return and conservation of trafficking machinery.
Soluble and membrane-bounded cargo moving in the anterograde direction are first
packaged into COPII coated vesicles at ER exit sites (Figure I, step 1). After shedding
their coats, COPII vesicles rapidly fuse to form a pleiomorphic Vesicular Tubular Cluster
(VTC), which is transported to the Golgi complex for possible maturation into the ER-
Golgi-Intermediate Compartment (ERGIC) (step 2). The VTC can also recycle
membranes to the ER via COPI coated vesicles (step 3) or receive COPI-dependent
retrograde traffic from the Golgi that is destined for the ER (step 4). Anterograde cargo
reaches the ERGIC, which may also constitute a biosynthetic precursor of the first Golgi
cisterna via a maturation process. The mammalian Golgi complex is composed of a stack
of cisternal membranes, with the cis-most receiving traffic from the ER and the trans-
most exporting cargo to other destinations. The mechanism by which cargo moves from
the cis to the trans Golgi remains under investigation [1]. Currently, three mechanisms
are in vogue: i) cisternal maturation where individual cisternae are remodeled by COPI-
dependent recycling of resident proteins (step 5), such that cis proteins become medial
and then trans; ii) formation of tubular connections between adjacent cisternae [2, 23];
and iii) rapid partitioning via a two-phase membrane system [25]. These mechanisms are
not mutually exclusive and their relative contributions could change to accommodate
physiological demand. For example, when a bolus of secretory protein is released from
the ER and reaches the Golgi, cisternae respond by elaborating membrane tubules, which
form intercisternal bridges that facilitate anterograde trafficking through the cisternal
stack (step 6). At the trans-most aspect is the TGN, which serves as the major depot for
vesicle- and tubule-mediated export to other parts of the cell (steps 7-9). PLA2 inhibitors
first revealed a role for phospholipase-dependent membrane tubules in Golgi transport
(red inhibitor symbols) [4, 5], the biogenesis of cisternae into large ribbon-like structures
(step 10), retrograde trafficking to the ER (step 11) [6], and export from the TGN (step 8)
[7]. Many of these steps are stimulated by brefeldin A (BFA) [76, 93-95, 103].
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Figure I.
A simplified diagram of the Golgi complex as a hub of membrane trafficking.
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Box 2. Outstanding questions
• Do PLA2 enzymes modify the shape of membranes by producing positive
curve-inducing lysophospholipids and/or by recruiting other factors that also
contribute to tubule formation?
• What are the molecular mechanisms used to recruit cytoplasmic PLA enzymes
specifically to Golgi subcompartments and not other organelles?
• How are the activities of these enzymes spatially and temporally regulated in
response to secretory load?
• Have all of the PLA enzymes directly involved in regulating Golgi (and
endosome) function been identified?
• Why do the Golgi complex, ERGIC and TGN respond to BFA by inducing
massive membrane tubular networks?
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Figure 1. Domain structures of Golgi- and ERGIC-associated PLA enzymes
cPLA2α contains a large α/β hydrolase domain with residues S228 and D549 comprising the
active site dyad. It also contains a C2 Ca2+-binding domain that is necessary for
translocation to Golgi membranes. PAFAH Ib is comprised of α1 and α2 homo- or
heterodimers together with LIS1. The indicated residues form the active site triad. iPLA2–β
contains a patatin lipase domain, with an active site at S519, and seven ankyrin repeats (I-
VII). iPLA1γ contains an S351 residue, which when mutated to alanine (A) abolishes
catalytic activity, a DDHD2 domain that is conserved with iPLA1β, a WWE domain
predicted to mediate protein-protein interactions in ubiquitination and ADP-ribosylation
systems, and a SAM domain (sterile alpha motif) that can mediate both homo- and hetero-
oligomerization.
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Figure 2. PLA enzymes that regulate the structure and function of the Golgi complex and
endosomes
cPLA2α localizes to the Golgi complex and mediates the formation of membrane tubules
that facilitate anterograde transport through the cisternal stack. The α1 and α2 PLA2
catalytic subunits of PAFAH Ib localize to multiple Golgi cisternae, early sorting endosomes
(ESEs), and the endocytic recycling compartment (ERC). These enzymes contribute to
membrane tubule formation that links cisternal stacks into intact Golgi ribbons and to those
that facilitate endocytic recycling of transferrin and its receptor from ESEs and the ERC. In
addition, loss of α1 and α2 inhibits export from the TGN, although it is not clear if this
involves membrane tubules. iPLA2–β localizes specifically to the ERGIC where it mediates
the formation of membrane tubules that bridge between separate ERGIC clusters. iPLA1γ
appears to localize primarily to the cis Golgi and may influence anterograde transport
through the cisternal stack.
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Figure 3. Model integrating membrane curvature produced by the PLA2 activity of PAFAH Ibα1 and α2 with Lis1-mediated dynein transport along microtubules
PAFAHIB initiates outward membrane curvature to generate a membrane tubule, which can
be pulled/extended along microtubules (MT) by Lis1 and Ndel interactions with dynein.
Dynein may be able to carry the membrane tubule towards the minus end of microtubules,
facilitating the convergence of the Golgi stack and positioning at the microtubule organizing
center (MTOC, minus end of the microtubules).
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